INTRODUCTION
Osteogenic sarcoma is a potentially lethal tumour, haematogenous spread carries the tumour first to the lung, and then elsewhere. In the pre-chemotherapy era treatment was by amputation and irradiation, but nevertheless 80% of patients had developed pulmonary secondaries within approximately two years (1-3). Un- treated, 88% of these were dead two years later, and all by five years (2-4). Surgical excision of multiple, and if necessary, recurrent pulmonary metastases led to improved results with 28% surviving 5 years (5). The addition of chemotherapy to the surgical treatment was found to further improve survival (6), and since 1974 has been adopted by many centres as the treatment of choice for these patients (3, 4, (7) (8) (9) (10) (11) (12) (13) (14) . Since 1976 However, these differences were not statistically signi- following amputation (25, 26) . The treatment of pulmonary secondaries by chemotherapy alone does little to influence the high mortality. Gundry (11) showed that 12 out of 13 patients with pulmonary secondaries treated this way had died after an average of seven months; Schaller (13) found that none survived without surgery. Han (3) reported that 80% of those with pulmonary metastases were dead within 18 months if they were not surgically resected.
Surgery alone, as treatment for pulmonary secondaries has met with more success. After Torek (1930) (27) , and Barney and Churchill (1939) (28) first excised pulmonary metastases in malignant disease, Sweetnam and Ross (29) reported that eight of 12 patients operated for solitary pulmonary metastases from bone tumours, had survived an average of 6.5 years. This led to an era of excision of the solitary secondary only, usually after some delay to confirm that no other metastasis was present (13, 29) . The use of surgery alone progressed so that conservative and, if necessary, repeated excision of multiple metastases was undertaken (3, 5, 9) 
